Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. RLMD
RLMD logo

RLMD News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

RLMD News

Relmada Therapeutics Q1 2026 Earnings Call Highlights

May 13 2026seekingalpha

Relmada Therapeutics Stock Rises After Piper Sandler Coverage Launch

Mar 24 2026seekingalpha

Relmada Reports 2025 Financials and Clinical Advancements

Mar 20 2026NASDAQ.COM

Relmada Therapeutics Financial Report Analysis

Mar 20 2026Yahoo Finance

Relmada (RLMD) Q4 2025 Earnings Call Transcript

Mar 20 2026NASDAQ.COM

Relmada Therapeutics Q4 Earnings Call Highlights

Mar 19 2026Yahoo Finance

Relmada Therapeutics Q4 Earnings Report Analysis

Mar 19 2026seekingalpha

Xenon and Relmada Surge on Positive Drug Data

Mar 09 2026Yahoo Finance

RLMD Events

03/09 16:20
Major Averages Volatile Amid Oil Price Spike
The major averages looked headed toward a down day amid another spike in oil prices due to the war in Iran and fears of broad stagflation. However, stocks rebounded into the green and oil prices declined after President Trump reportedly told a CBS reporter that the Iran war could be over soon, being quoted by CBS News Senior White House Correspondent Weijia Jiang asthat he thinks the war is "very complete, pretty much." Meanwhile, the Financial Times reported that G7 officials are considering tapping into strategic reserves.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Hims & Hersreached a pact with Novo Nordiskto bringLive Nationis near a settlement with the U.S. Department of Justice under which it may avoid selling Ticketmaster,Universal HealthTalkspacefor $5.25 per shareOpenAIAI security platform PromptfooAirlines are reconsidering growth plans amid the war in Iran,2. WALL STREET CALLS:Verizonto Outperform from Sector Perform at ScotiabankGE Vernovato Buy from Sell at Rothschild & Co RedburnuniQureat RBC Capital and Wells Fargo after news of Vinay Prasad leaving FDAJefferies Financialto Equal Weight at Morgan StanleyStarbucksto Peer Perform at Wolfe Research as a new analyst took over coverage3. AROUND THE WEB:Appleis pushing back the planned launch of its smart home display, Bloomberg saysAirbusis debating on a joint bid with Rheinmetalland OHB to build an internet service for the Bundeswehr armed forces, Bloomberg reportsTencentplans to invest several hundred million dollars on Paramount Skydance'sacquisition of Warner Bros Discovery, Bloomberg reportsKKRis working on a sale of CoolIT Systems, hoping to fetch a price tag in excess of $3B, The Financial Times reportsSamsung'sconsumer device chief TM Roh says the company is "open to strategic co-operation" with more AI groups, FT reports4. MOVERS:Xene Pharmaceuticalsgained after announcing its Phase 3 X-TOLE2 studyRelmadaincreased after reporting 12-month Phase 2Dianthusadvanced afterand announcing an early GO decision based on its Phase 3 trial of claseprubartOric Pharmaceuticalsfell after rival drugmaker Ipsenannounced it isin all indications from all Ipsen marketsFuelCellclosed lower after5. EARNINGS/GUIDANCE:Nayax, with CEO Yair Nechmad commenting, "Nayax delivered strong 2025 results and a very solid fourth quarter"Korn Feryand provided guidance for Q4ARS Pharmaceuticals, with EPS and revenue beating consensusSignet Jewelersprovidedand FY26Genius Groupreportedand provided guidance for FY26INDEXES:The Dow rose 239.25, or 0.50%, to 47,740.80, the Nasdaq gained 308.26, or 1.38%, to 22,695.95, and the S&P 500 advanced 55.97, or 0.83%, to 6,795.99.

RLMD Monitor News

Relmada Secures $160 Million in PIPE Financing

Mar 09 2026

RLMD Earnings Analysis

No Data

No Data

People Also Watch